Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase I/II study of orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
CTR20180263Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Innovent Biologics. Started Apr 2018; status: active.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20180263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180263.